Literature DB >> 9710098

Exogenous surfactant and positive end-expiratory pressure in the treatment of endotoxin-induced lung injury.

C J Lutz1, A Picone, L A Gatto, A Paskanik, S Landas, G F Nieman.   

Abstract

OBJECTIVE: To evaluate the efficacy of treating endotoxin-induced lung injury with single dose exogenous surfactant and positive end-expiratory pressure (PEEP).
DESIGN: Prospective trial.
SETTING: Laboratory at a university medical center.
SUBJECTS: Nineteen certified healthy pigs, weighing 15 to 20 kg.
INTERVENTIONS: Pigs were anesthetized and surgically prepared for hemodynamic and lung function measurements. Animals were randomized into four groups: a) Control pigs (n = 4) received an intravenous infusion of saline without Escherichia colilipopolysaccharide (LPS); b) the LPS group (n = 5) received an intravenous infusion of saline containing LPS (100 microg/kg); c) the PEEP plus saline group (n = 5) received an intravenous infusion of saline containing LPS. Two hours after LPS infusion, saline was instilled into the lung as a control for surfactant instillation, and the animals were placed on 7.5 cm H2O of PEEP; d) the PEEP plus surfactant group (n = 5) received an intravenous infusion of saline containing LPS. Two hours following LPS infusion, surfactant (50 mg/kg) was instilled into the lung and the animals were placed on 7.5 cm H2O of PEEP. PEEP was applied first and surfactant or saline was instilled into the lung while maintaining positive pressure ventilation. All groups were studied for 6 hrs after the start of LPS injection. At necropsy, bronchoalveolar lavage was performed and the right middle lung lobe was fixed for histologic analysis.
MEASUREMENTS AND MAIN RESULTS: Compared with LPS without treatment, PEEP plus surfactant significantly increased PaO2 (PEEP plus surfactant = 156.6 +/- 18.6 [SEM] torr [20.8 +/- 2.5 kPa]; LPS = 79.2 +/- 21.9 torr [10.5 +/- 2.9 kPa]; p<.05), and decreased venous admixture (PEEP plus surfactant = 12.5 +/- 2.0%; LPS = 46.9 +/- 14.2%; p< .05) 5 hrs after LPS infusion. These changes were not significant 6 hrs after LPS infusion. PEEP plus surfactant did not alter ventilatory efficiency index (VEI = 3800/[peak airway pressure - PEEP] x respiratory rate x PacO2), or static compliance as compared with LPS without treatment at any time point. Cytologic analysis of bronchoalveolar lavage fluid showed that surfactant treatment significantly increased the percentage of alveolar neutrophils as compared with LPS without treatment (PEEP plus surfactant = 39.1 +/- 5.5%; LPS = 17.4 +/- 6.6%; p< .05). Histologic analysis showed that LPS caused edema accumulation around the airways and pulmonary vessels, and a significant increase in the number of sequestered leukocytes (LPS group = 3.4 +/- 0.2 cells/6400 micro2; control group = 1.3 +/- 0.1 cells/6400 micro2; p < .05). PEEP plus saline and PEEP plus surfactant significantly increased the total number of sequestered leukocytes in the pulmonary parenchyma (PEEP plus surfactant = 8.2 +/- 0.7 cells/6400 micro2; PEEP plus saline = 3.9 +/- 0.2 cells/6400 micro2; p <.05) compared with the control and LPS groups.
CONCLUSIONS: We conclude that PEEP plus surfactant treatment of endotoxin-induced lung injury transiently improves oxygenation, but is unable to maintain this salutary effect indefinitely. Thus, repeat bolus dosing of surfactant or bolus treatment followed by continuous aerosol delivery may be necessary for a continuous beneficial effect.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9710098     DOI: 10.1097/00003246-199808000-00025

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  8 in total

1.  Surfactant administration prior to one lung ventilation: physiological and inflammatory correlates in a piglet model.

Authors:  Rahul Bhatia; Thomas H Shaffer; Jobayer Hossain; Alicia Olivant Fisher; Liana M Horner; M Elena Rodriguez; Scott Penfil; Mary C Theroux
Journal:  Pediatr Pulmonol       Date:  2011-05-26

Review 2.  Surfactant therapy for acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; D Willson; R H Notter
Journal:  Crit Care Clin       Date:  2011-07       Impact factor: 3.598

3.  An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals.

Authors:  Gustavo Matute-Bello; Gregory Downey; Bethany B Moore; Steve D Groshong; Michael A Matthay; Arthur S Slutsky; Wolfgang M Kuebler
Journal:  Am J Respir Cell Mol Biol       Date:  2011-05       Impact factor: 6.914

Review 4.  Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; Gloria S Pryhuber; Patricia R Chess; Bruce A Davidson; Paul R Knight; Robert H Notter
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 5.  Surfactant for pediatric acute lung injury.

Authors:  Douglas F Willson; Patricia R Chess; Robert H Notter
Journal:  Pediatr Clin North Am       Date:  2008-06       Impact factor: 3.278

Review 6.  Pediatric Acute Respiratory Distress Syndrome: Fibrosis versus Repair.

Authors:  Daniel Im; Wei Shi; Barbara Driscoll
Journal:  Front Pediatr       Date:  2016-03-30       Impact factor: 3.418

7.  Synthetic surfactant with a recombinant surfactant protein C analogue improves lung function and attenuates inflammation in a model of acute respiratory distress syndrome in adult rabbits.

Authors:  J Zebialowicz Ahlström; F Massaro; P Mikolka; R Feinstein; G Perchiazzi; O Basabe-Burgos; T Curstedt; A Larsson; J Johansson; A Rising
Journal:  Respir Res       Date:  2019-11-06

8.  Impact of synthetic surfactant CHF5633 with SP-B and SP-C analogues on lung function and inflammation in rabbit model of acute respiratory distress syndrome.

Authors:  Pavol Mikolka; Tore Curstedt; Riccardo Feinstein; Anders Larsson; Marian Grendar; Anna Rising; Jan Johansson
Journal:  Physiol Rep       Date:  2021-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.